3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Gastrointestinal
3
Thoracic
2
Breast
2
Tumor-Agnostic
1
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Carcinoma, Neuroendocrine
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Doxorubicin
4
Sunitinib
3
Radiosurgery
3
Everolimus
3
pembrolizumab
2
exemestane
2
Tamoxifen
2
Specimen Handling
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Filgrastim
2
Biopsy
2
Bevacizumab
2
3-Iodobenzylguanidine
2
tislelizumab
1
surufatinib
1
romidepsin
1
regorafenib
1
penpulimab
1
pasireotide
1
mercaptoundecahydrododecaborate
1
lutetium Lu 177 dotatate
1
lanreotide
1
ganitumab
1
folfirinox
1
fludarabine phosphate
1
epothilone B
1
entrectinib
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
dostarlimab
×
Endocrine
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled